| 000 | 00843 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250513071201.0 | ||
| 264 | 0 | _c19940217 | |
| 008 | 199402s 0 0 eng d | ||
| 022 | _a0959-8138 | ||
| 024 | 7 |
_a10.1136/bmj.307.6914.1223 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBristow, M F | |
| 245 | 0 | 0 |
_aHow "malignant" is the neuroleptic malignant syndrome? _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cNov 1993 |
||
| 300 |
_a1223-4 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aCreatine Kinase _xanalysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeuroleptic Malignant Syndrome _xenzymology |
| 700 | 1 | _aKohen, D | |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 307 _gno. 6914 _gp. 1223-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.307.6914.1223 _zAvailable from publisher's website |
| 999 |
_c8280329 _d8280329 |
||